Advertisement Actavis rolls out anti epileptic drug - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Actavis rolls out anti epileptic drug

Actavis Group's US subsidiary Actavis has rolled out Levetiracetam Extended-Release Tablets to treat partial-onset seizures in patients with epilepsy.

Levetiracetam Extended-Release Tablets are the generic version of Keppra XR of UCB.

Keppra is an anti-epileptic drug which is indicated for the treatment of partial onset seizures in patients 16 years of age and older with epilepsy.

Actavis is engaged in the development, manufacture and sale of generic pharmaceuticals.